Abstract
AbstractNeisseria meningitidis is a major cause of bacterial meningitidis worldwide. Children less than five years and adolescents are particularly affected. Nearly all invasive strains are surrounded by a polysaccharide capsule, based on which, 12 N. meningitidis serogroups are differentiated. Six of them, A, B, C, W, X, and Y, cause the vast majority of infections in humans. Mono- and multi-valent carbohydrate-based vaccines against meningococcal infections have been licensed or are currently in clinical development. In this mini-review, an overview of the past and present approaches for producing meningococcal glycoconjugate vaccines is provided.
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology,Biochemistry
Reference78 articles.
1. Pizza, M., Rappuoli, R.: Neisseria meningitidis: pathogenesis and immunity. Curr. Opin. Microbiol. 23, 68–72 (2015)
2. Organization, W.H.: Control of epidemic meningococcal disease, p. Practical Guidelines. 2nd edn. Geneva (1988)
3. Rosenstein, N.E., et al.: Meningococcal disease. N. Engl. J. Med. 344(18), 1378–1388 (2001)
4. Shah, S., Gross, J.R., Stewart, C.T.: A case report of meningococcal disease in a neonate. Wmj 112(1), 28–30 (2013); quiz 31
5. Harrison, L.H., Trotter, C.L., Ramsay, M.E.: Global epidemiology of meningococcal disease. Vaccine 27, B51–B63 (2009)
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献